Abstract
In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.
| Original language | English |
|---|---|
| Pages (from-to) | 245-255 |
| Number of pages | 11 |
| Journal | Multiple Sclerosis Journal |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2018 |
Fingerprint
Keywords
- bone marrow transplantation
- Haematopoietic stem cell transplantation
- intense immunosuppression
- multiple sclerosis
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. / Mancardi, Gianluigi; Sormani, Maria Pia; Muraro, Paolo A.; Boffa, Giacomo; Saccardi, Riccardo.
In: Multiple Sclerosis Journal, Vol. 24, No. 3, 01.03.2018, p. 245-255.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis
AU - Mancardi, Gianluigi
AU - Sormani, Maria Pia
AU - Muraro, Paolo A.
AU - Boffa, Giacomo
AU - Saccardi, Riccardo
PY - 2018/3/1
Y1 - 2018/3/1
N2 - In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.
AB - In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure. A description of the ideal patient who can take advantage of aHSCT is outlined and, finally, the ongoing studies which are near to completion or are close to starting are briefly reported.
KW - bone marrow transplantation
KW - Haematopoietic stem cell transplantation
KW - intense immunosuppression
KW - multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85042877198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042877198&partnerID=8YFLogxK
U2 - 10.1177/1352458517742532
DO - 10.1177/1352458517742532
M3 - Review article
AN - SCOPUS:85042877198
VL - 24
SP - 245
EP - 255
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 3
ER -